Literature DB >> 24753548

Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation.

Jeffrey I Weitz1, Jeffrey S Healey, Allan C Skanes, Atul Verma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24753548     DOI： 10.1161/CIRCULATIONAHA.113.005376

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  9 in total

1.  Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.

Authors:  Melanie Gunawardene; S Willems; B Schäffer; J Moser; R Ö Akbulak; M Jularic; C Eickholt; J Nührich; C Meyer; P Kuklik; S Sehner; V Czerner; B A Hoffmann
Journal:  Clin Res Cardiol       Date:  2016-07-19       Impact factor: 5.460

2.  Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs.

Authors:  Philippe Maury; Slimane Belaid; Agnès Ribes; Quentin Voglimacci-Stephanopoli; Pierre Mondoly; Marie Blaye; Franck Mandel; Benjamin Monteil; Didier Carrié; Michel Galinier; Vanina Bongard; Anne Rollin; Sophie Voisin
Journal:  J Arrhythm       Date:  2020-05-19

Review 3.  Big Data and Atrial Fibrillation: Current Understanding and New Opportunities.

Authors:  Qian-Chen Wang; Zhen-Yu Wang
Journal:  J Cardiovasc Transl Res       Date:  2020-05-06       Impact factor: 4.132

4.  Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.

Authors:  Riccardo Cappato; Francis E Marchlinski; Stefan H Hohnloser; Gerald V Naccarelli; Jim Xiang; David J Wilber; Chang-Sheng Ma; Susanne Hess; Darryl S Wells; George Juang; Johan Vijgen; Burkhard J Hügl; Richard Balasubramaniam; Christian De Chillou; D Wyn Davies; L Eugene Fields; Andrea Natale
Journal:  Eur Heart J       Date:  2015-05-14       Impact factor: 29.983

Review 5.  Novel oral anticoagulants in non-valvular atrial fibrillation.

Authors:  Rose M F L da Silva
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2014

6.  Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.

Authors:  Rong-Feng Zhang; Cheng-Ming Ma; Na Wang; Ming-Hui Yang; Wen-Wen Li; Xiao-Meng Yin; Ying-Xue Dong; Xiao-Hong Yu; Xian-Jie Xiao; Yun-Long Xia; Lian-Jun Gao
Journal:  BMC Cardiovasc Disord       Date:  2021-04-27       Impact factor: 2.298

Review 7.  Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?

Authors:  Michael Hardy; Jonathan Douxfils; Anne-Sophie Dincq; Anne-Laure Sennesael; Olivier Xhaet; Francois Mullier; Sarah Lessire
Journal:  Front Cardiovasc Med       Date:  2022-03-29

Review 8.  Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

Authors:  Mate Vamos; Riccardo Cappato; Francis E Marchlinski; Andrea Natale; Stefan H Hohnloser
Journal:  Europace       Date:  2016-01-20       Impact factor: 5.214

9.  How minimally interrupted direct oral anticoagulants affect intraprocedural anticoagulation during atrial fibrillation ablation? Insights from a Japanese single-center retrospective study.

Authors:  Masahiro Mizobuchi; Atsushi Funatsu; Tomoko Kobayashi; Shigeru Nakamura
Journal:  J Arrhythm       Date:  2019-08-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.